Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Inc. - Common Stock (NQ:IXHL)

2.790 -0.070 (-2.45%)
Delayed Quote Updated: 2:46 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Incannex Approved For Bioavailability Clinical Trial For Dronabinol-Based Drug For Treatment Of Obstructive Sleep Apnea ↗
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
Via Talk Markets
News headline image
Incannex appoints principal investigators for pivotal IHL-42X trial
Incannex appoints principal investigators for pivotal IHL-42X trial 
Via News Direct
Incannex appoints principal investigators for pivotal IHL-42X trial
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X,... 
Via TheNewswire.com
News headline image
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
Via Talk Markets
News headline image
Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index 
Via Talk Markets
News headline image
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More ↗
Major Investor Commits $30 Million To Psychedelics Funding 
Via Benzinga
News headline image
Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes ↗
NCIA Sacks Half Of Its Team To Increase Financial Strength 
Via Benzinga
News headline image
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances ↗
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
Via Talk Markets
Incannex welcomes world-leading psychedelics experts to advisory board
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) director Peter Widdows tells Proactive the company has appointed three world-renowned psychedelic therapy and science experts to its Clarion Clinics Group... 
Via TheNewswire.com
News headline image
Incannex welcomes world-leading psychedelics experts to advisory board
Incannex welcomes world-leading psychedelics experts to advisory board 
Via News Direct
News headline image
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More ↗
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
News headline image
Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary ↗
Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd. 
Via Benzinga
News headline image
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
News headline image
Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic ↗
Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne. 
Via Benzinga
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics... 
Via TheNewswire.com
News headline image
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A 
Via News Direct
News headline image
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More ↗
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
News headline image
April Psychedelic Drug Stocks Recap: The Ups And Downs ↗
Via Talk Markets
News headline image
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market ↗
Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual... 
Via Benzinga
News headline image
Largest Psychedelic Stocks -3.4% In March ↗
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts. 
Via Talk Markets
News headline image
Cannabis Category Performances Ranged From +8.6% To -7.0% This Week ↗
The 5 categories in the cannabis sector perform quite differently from each other and this week was a prime example. 
Via Talk Markets
News headline image
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
News headline image
Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary ↗
Australia-based biopharma giant Incannex Healthcare Ltd. (NASDAQ: IXHL) has plans to commercialize its psychedelic-assisted psychotherapy business through a new subsidiary venture under the leadership... 
Via Benzinga
News headline image
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder ↗
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. 
Via Benzinga
News headline image
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.